Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q3 FY22-23 Earnings Presentation
29 slides from Gujarat Themis Biosyn's earnings presentation, Feb 6, 2023
Slide 1: Investor Presentation cover letter to BSE
GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY : 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL : 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net GTBL: CS: BSE-CORR/2022-23 6th February, 2023 To, BSE Limited, Floor 25, Phiroze Jeejeebhoy T
Slide 2: Result Update Presentation Q3 & 9M FY22-23
Gujarat Themis Biosyn Limited Result Update Presentation Q3 & 9M FY22-23
Slide 3: Disclaimer
Click to edit Master title style Disclaimer This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” or “GTBL”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form t
Slide 4: Table of Contents
Click to editofMaster Table title style Contents Company Overview Business Overview Industry Overview Financial Highlights Way Ahead 3
Slide 5: Company Overview
Company Overview
Slide 6: Fermentation based Intermediate manufacturer
Click Among to edit India’s Masterfew title style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation-based manufacturer in pharmaceutical field State of Art Manufacturing Facility Incorporated in 1981 as joint Plant in Vapi (Gujarat) sector Company with GIIC
Slide 7: Journey So Far
Click to edit Master Journey So Far title style BIFR declared GTBL as sick Repaid total Company working capital Established as joint Dr. Dinesh Patel stepped in as Production sector Company with loan Entered into JV agreement Guarantor and Adviser Deregistration continues Govt of Gujar
Slide 8: Expert and Experienced Management Team
Click to edit and Expert Master title style Experienced Management Team Dr. Dinesh Patel Dr. Sachin Patel Chairman Director Doctorate in Medicinal Chemistry Member of Royal Society of Chemistry, London, U.K. Doctorate in Biological chemistry from Christ's College, Industrialist having more t
Slide 9: Key Strengths
Click to Keyedit Master title style Strengths Strong Product Portfolio Demand side remains strong for product manufactured 01 by GTBL More than decade old products with no replacement for these Continued to be most accepted and preferred products Investments in R&D 02 with growing demand New
Slide 10: Business Overview
Business Overview
Slide 11: Product Portfolio – Growing at pace
Click toStrong edit Master & Niche title style Product Portfolio – Growing at pace Current Product Portfolio Rifamycin An intermediate for Rifamycin S An intermediate for manufacturing drug Rifampicin O manufacturing drug Rifaximin (Anti biotic used for treatment of (Antibiotic used for treatmen
Slide 12: Advantages of using Unique Fermentation Process
Advantages Click to of using edit Master title the styleUnique Fermentation Process Fermentation Process Fermentation Broth Solid / Liquid Lab Filtration Separation GTBL and Fermentation Technology - Strive to develop new fermentation culture: Fermentation is the core competency of Company Primary
Slide 13: State of the Art Manufacturing Facilities at Vapi
Click to editofMaster State title style Facilities at Vapi Art Manufacturing Among very few companies in India with fermentation capabilities for Intermediates Environment Friendly & Sustainable Process Using Aerobic Bacteria for Fermentation 12
Slide 14: Industry Overview
Industry Overview
Slide 15: Pharmaceutical Market – An Overview
Click to edit Master title Pharmaceutical styleAn Overview Market- Active Pharmaceutical Ingredient Market valued at USD 209.7 Billion in 2021 and expected to grow at North America-expected to dominate Active Global Market 01 02 CAGR of 6.0% during 2022-30 to reach USD 353 billion Pharmaceutical Ing
Slide 16: The Indian Pharma Advantage
Click to Theedit Master Indian titleAdvantage Pharma style Low cost of production & R&D boosts efficiency of Indian pharma companies, leading to competitive exports Cost Efficiency 01 India’s cost of production is approximately 33% lower than that of US India’s ability to manufacture high-qual
Slide 17: Q3 & 9M FY22-23 Financial Highlights
Q3 & 9M FY22-23 Financial Highlights
Slide 18: Quarterly Financial Highlights
Click to edit Master Quarterly titleHighlights Financial style Revenue (Rs. Cr) 44.94 47.69 35.05 28.76 28.17 18.60 Q2 FY21-22 Q3 FY21-22 Q4 FY21-22 Q1 FY22-23 Q2 FY22-23 Q3 FY22-23 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 25 52.63% 52.66% 50.68% 51.17% 60% 45.47% 39.35% 39.54% 39.21%
Slide 19: Q3 FY22-23 Financial Highlights
Click to Q3edit Master FY22-23 title style Financial Highlights Rs. Crs Q3 FY22-23 Q3 FY21-22 YoY% Q2 FY22-23 Income from Operations 28.17 18.60 47.69 Other Operating Income 0.00 0.00 0.00 Total Income from Operations 28.17 18.60 51.40% 47.69 Cost of Materials Consumed 7.44 6.43 7.66 Changes In Inve
Slide 20: 9M FY22-23 Financial Highlights
Click to 9Medit Master FY22-23 title style Financial Highlights Rs. Crs 9M FY22-23 9M FY21-22 YoY% Income from Operations 120.80 86.09 Other Operating Income 0.00 0.00 Total Income from Operations 120.80 86.09 40.32% Cost of Materials Consumed 22.77 18.56 Changes In Inventory 1.74 (8.17) Employee Co
Slide 21: Annual Financial Highlights
Annual Financial Highlights
Slide 22: Financial Highlights – FY21-22 vs FY20-21
Click to edit Master Financial title–style Highlights FY21-22 vs FY20-21 26.82% 43.93% 601 bps Revenue from Operations EBITDA EBITDA Margin Rs. 114.85 Crore Rs. 58.05 Crore 50.54% 44.55% 466 bps 44.58% PAT PAT Margin Basic EPS Rs. 43.62 Crore 37.98% Rs. 30.03 vs. Rs 20.77 in FY2021 21
Slide 23: Annual Financial Highlights
Click to edit Master Annual Financialtitle style Highlights Revenue (Rs. Cr) 114.85 85.12 90.56 38.80 41.05 FY17-18 FY18-19 FY19-20 FY2021 FY21-22 EBITDA (Rs. Cr) / Margin (%) PAT (Rs. Cr) / Margin (%) 70 60% 50.5% 38.0% 60 50 40% 44.5% 50% 33.3% 37.4% 45 27.8% 35% 50 40 43.6 40% 30% 35 40 15.6% 25%
Slide 24: Annual Financial Highlights – FY21-22
Click to edit Master Annual Financialtitle style – FY21-22 Highlights Rs. Crs FY21-22 FY20-21 YoY% Income from Operations 114.85 90.56 Other Operating Income 0.00 0.00 Total Income from Operations 114.85 90.56 26.82% Cost of Materials Consumed 21.75 15.75 Changes In Inventory (5.13) (0.38) Employee
Slide 25: Balance Sheet Highlights – As on 30th September 2022
Click to edit Master Balance title style– As on 30th September 2022 Sheet Highlights Rs. Cr. Rs. Cr. Sep 2022 Mar 2022 Sep 2022 Mar 2022 Total Equity & Liabilities Total Assets Shareholders Funds 133.94 103.32 Non Current Assets 53.20 44.11 Share Capital 7.26 7.26 18.21 18.22 Property Plant & Equipm
Slide 26: Key Balance Sheet Ratios
Click to Keyedit Master Balance title Sheet style Ratios RoCE(%)* RoA(%)** 37.0% 35.6% 70.91% 34.2% 59.9% 57.9% 41.40% 18.9% 19.6% 33.94% FY17-18 FY18-19 FY19-20 FY20-21 FY21-22 FY17-18 FY18-19 FY19-20 FY20-21 FY21-22 RoE(%)*** 56.1% 43.2% 42.2% 32.2% 34.6% FY17-18 FY18-19 FY19-20 FY20-21 FY21-22 **
Slide 27: Way Ahead
Way Ahead
Slide 28: Our Way Ahead
Click to Ouredit Way Master Aheadtitle style In process of identifying new products which have good domestic and export New Product Development & potential Company working on strategy to move up the value chain by way of forward Forward Integration integration into API New infrastructure being
Slide 29: Thank You
Click to editYou Thank Master title style For further information, please contact: Company : Investor Relations Advisors : Gujarat Themis Biosyn Limited Bridge Investor Relations Pvt. Ltd. Mr. Sangameshwar Iyer Ms. Savli Mangle - 9833361003 Mr. Rahul Trivedi - 9833541841 sangameshwar.iyer@themismedi
Gujarat Themis Biosyn — Q3 FY22-23 Earnings Presentation on 6ix